

NCIC CLINICAL TRIALS GROUP

LUNG SITE

EXECUTIVE COMMITTEE MEETING
AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Saturday, April 28, 2007 - 7:00 a.m – 8:15 p.m EST
Room: Scott

Chair: Dr. Frances Shepherd

REPORT FROM RETREAT

OPEN TRIAL WITH ISSUES

BR.24 AZD 2171 in advanced Non-SCLC – Toxicity review

NEW STUDIES UNDER CONSIDERATION FOR PRIORITIZATION

SMALL CELL LUNG CANCER TRIALS

Proposals and decision re radiation trial for LD SCLC
Chemotherapy + / - low molecular weight heparin
Etoposide / platinum + / - pomalidomide in extensive SCLC

NON-SMALL CELL LUNG CANCER TRIALS

CTEP/FDA/C-PATH Initiative to develop studies to assess and approve biomarkers -
N0723 - A Phase III biomarker validation study of second-line therapy in patients with
advanced NSCLC randomized to pemetrexed versus erlotinib.

IND STUDIES

Report from the IND committee re new trials

DATA-BASE ANALYSES AND OTHER TRIAL-RELATED PROJECTS

Correlative Sciences Working Group Report

OTHER BUSINESS